GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2008

Novartis Raises Ownership in Alnylam with $5.41M Procurement of Shares

  • Novartis has purchased additional shares of Alnylam Pharmaceuticals’ common stock for almost $5.41 million. The decision to fully exercise this right increases Novartis’ stake in Alnylam from 13% to 13.4%.

    As per the terms of a September 2005 investor rights agreement between the companies, Novartis decided to buy  213,888 unregistered shares of Alnylam’s common stock. The firm is paying $25.29 per share. Alnylam value at the end of yesterday was $24.84 and opened trading today at $25.51.

    Novartis previously purchased approximately 5.3 million shares at $11.11 per share, gaining a 13% ownership position. The company is permitted to own no more than 19.9% of Alnylam’s outstanding shares.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »